CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF
Novel crystalline polymorphic forms, Forms A, B, C, D, and E of a compound of Formula I, which has been found to be a potent inhibitor of LFA-1, are disclosed. Methods of preparation and uses thereof in the treatment of LFA-1 mediated diseases are also disclosed in this invention.
1 - 67 . (canceled)
68 . A method for treating diabetic macular edema in a subject in need thereof, comprising administering to the subject an effective amount of a composition comprising a compound of Formula I:
or a pharmaceutically acceptable salt thereof, wherein said compound comprises a purity of greater than about 90 percent.
69 . The method of claim 68 , wherein said compound has a purity of greater than about 98 percent.
70 . The method of claim 68 , wherein said compound comprises at least about 95 percent of an S-enantiomer.
71 . The method of claim 68 , wherein said compound is a sodium salt.